Oncolytic measles viruses for cancer therapy
- PMID: 15461580
- DOI: 10.1517/14712598.4.10.1685
Oncolytic measles viruses for cancer therapy
Abstract
New strategies using biological agents are being developed to treat cancer. Live viruses are among these new agents. Virotherapy uses replication-competent viral vectors with strong oncolytic properties. With the use of molecular virology techniques, viruses have been genetically engineered to replicate selectively in tumour cells and are under preclinical and clinical investigation at present. Measles virus (MV) is being used for this purpose. Replication-competent attenuated Edmonston B measles vaccine strain (MV-Edm) is non-pathogenic and has potent antitumour activity against several human tumours. The virus is selectively oncolytic in tumour cells, eliciting extensive cell-to-cell fusion and ultimately leading to cell death. Therefore, MV-Edm is a safe and efficient means to kill tumour cells. Further improvements in existing MV vectors may increase tumour selectivity and oncolytic activity. This review discusses the discovery and development of replication-competent oncolytic MV for cancer therapy.
Similar articles
-
Engineered measles virus as a novel oncolytic therapy against prostate cancer.Prostate. 2009 Jan 1;69(1):82-91. doi: 10.1002/pros.20857. Prostate. 2009. PMID: 18973133 Free PMC article.
-
Measles virus selectively blind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment.Gene Ther. 2013 Mar;20(3):338-47. doi: 10.1038/gt.2012.44. Epub 2012 Jun 21. Gene Ther. 2013. PMID: 22717740
-
Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma.Hepatology. 2006 Dec;44(6):1465-77. doi: 10.1002/hep.21437. Hepatology. 2006. PMID: 17133484
-
Measles virus as an oncolytic vector platform.Curr Gene Ther. 2008 Jun;8(3):162-75. doi: 10.2174/156652308784746459. Curr Gene Ther. 2008. PMID: 18537591 Review.
-
Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccination.Hum Vaccin Immunother. 2016 May 3;12(5):1102-16. doi: 10.1080/21645515.2015.1122146. Epub 2015 Dec 2. Hum Vaccin Immunother. 2016. PMID: 26631840 Free PMC article. Review.
Cited by
-
Retargeted and Stealth-Modified Oncolytic Measles Viruses for Systemic Cancer Therapy in Measles Immune Patients.Mol Cancer Ther. 2020 Oct;19(10):2057-2067. doi: 10.1158/1535-7163.MCT-20-0134. Epub 2020 Aug 26. Mol Cancer Ther. 2020. PMID: 32847970 Free PMC article.
-
Retargeting of viruses to generate oncolytic agents.Adv Virol. 2012;2012:798526. doi: 10.1155/2012/798526. Epub 2011 Nov 14. Adv Virol. 2012. PMID: 22312365 Free PMC article.
-
In vivo safety, biodistribution and antitumor effects of uPAR retargeted oncolytic measles virus in syngeneic cancer models.Gene Ther. 2014 Mar;21(3):289-97. doi: 10.1038/gt.2013.84. Epub 2014 Jan 16. Gene Ther. 2014. PMID: 24430235 Free PMC article.
-
Repurposing Infectious Diseases Vaccines Against Cancer.Front Oncol. 2021 May 13;11:688755. doi: 10.3389/fonc.2021.688755. eCollection 2021. Front Oncol. 2021. PMID: 34055652 Free PMC article. Review.
-
High pathogenicity of wild-type measles virus infection in CD150 (SLAM) transgenic mice.J Virol. 2006 Jul;80(13):6420-9. doi: 10.1128/JVI.00209-06. J Virol. 2006. PMID: 16775330 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources